Controlled-release carbamazepine matrix granules and tablets comprising lipophilic and hydrophilic components

Controlled-Release Carbamazepine Matrix Granules and Tablets Comprising Lipophilic and Hydrophilic Components

The objective of this study was to investigate the effect of lipophilic (Compritol 888 ATO) and hydrophilic components (combination of HPMC and Avicel) on the release of carbamazepine from granules and corresponding tablet. Wet granulation followed by compression was employed for preparation of granules and tablets. The matrix swelling behavior was investigated. The dissolution profiles of each...

preparation and evaluation of zinc sulfate sustained release tablets using lipophilic and hydrophilic matrix

Parmacokinetic evaluation of ibuprofen controlled release matrix tablets using hydrophilic Eudragit® polymer and co-excipients.

The present study was conducted to formulate controlled release dosage forms containing Ibuprofen with Eudragit® S 100 polymer. The tablets were formulated at three different ratios with the polymer to investigate the effect of different concentrations of polymer on in vitro drug release patterns/kinetics and in vivo absorption/pharmacokinetics. Pre-formulation studies were conducted including ...

In Vitro Studies of Controlled Release Alfuzosin Matrix Tablets Prepared with Ethylcellulose and Hydroxypropyl Methylcellulose

      Extended release formulation of alfuzosin, an a-antagonist used for prostatic hypertrophy, is available in market. It is convenient for older patients to take only one tablet a day. Marketed alfuzosin formulation is three layered geomatrix tablet that requires special facilities, high cost, more time and complex operation than normal direct compression formulation. Therefore, a less compl...

Development of orally disintegrating tablets comprising controlled-release multiparticulate beads

Melperone is an atypical antipsychotic agent that has shown a wide spectrum of neuroleptic properties, particularly effective in the treatment of senile dementia and Parkinson's-associated psychosis, and is marketed in Europe as an immediate-release (IR) tablet and syrup. An orally disintegrating tablet (ODT) dosage form would be advantageous for patients who experience difficulty in swallowing...